Format

Send to

Choose Destination
See comment in PubMed Commons below
Semin Cancer Biol. 2012 Feb;22(1):3-13. doi: 10.1016/j.semcancer.2011.12.009. Epub 2012 Jan 8.

Monoclonal antibodies for the treatment of cancer.

Author information

1
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, United States. cws39@georgetown.edu

Abstract

Over the past decade, the clinical utility of monoclonal antibodies has been realized and antibodies are now a mainstay for the treatment of cancer. Antibodies have the unique capacity to target and kill tumor cells while simultaneously activating immune effectors to kill tumor cells through the complement cascade or antibody-dependent cellular cytotoxicity (ADCC). This multifaceted mechanism of action combined with target specificity underlies the capacity of antibodies to elicit anti-tumor responses while minimizing the frequency and magnitude of adverse events. This review will focus on mechanisms of action, clinical applications and putative mechanisms of resistance to monoclonal antibody therapy in the context of cancer.

PMID:
22245472
PMCID:
PMC3288558
DOI:
10.1016/j.semcancer.2011.12.009
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center